Ge Long Hui A P P·2026-02-26 08:22Core Viewpoint - The company reported a significant improvement in its financial performance for the fiscal year 2025, achieving a total revenue of approximately 1.068 billion yuan, marking a year-on-year growth of 26.18% [1] Financial Performance - The net profit attributable to the parent company's owners was approximately 27.87 million yuan, indicating a turnaround from a loss to profit compared to the same period last year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was approximately -92.50 million yuan [1] Strategic Initiatives - The company continues to focus on innovation and commercialization as key components of its development strategy, with the revenue from its first quadrivalent meningococcal vaccine, Manhaixin®, showing sustained growth [1] - Cost reduction and efficiency improvement measures have been effectively implemented, leading to better expense management [1] - The optimization of production and sales coordination has contributed to an increase in gross profit margin [1] Research and Development - The company is advancing its R&D projects rapidly and has engaged in international collaborations, receiving government special subsidies and international research funding [1] - The recognition of related non-recurring income during the reporting period reflects the support received for its R&D efforts [1]